# Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

> **NCT00108069** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Tamoxifen citrate
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00108069
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108069, "Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00108069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*